ES2103276T3 - Composicion para la activacion del sistema inmunitario. - Google Patents

Composicion para la activacion del sistema inmunitario.

Info

Publication number
ES2103276T3
ES2103276T3 ES90914341T ES90914341T ES2103276T3 ES 2103276 T3 ES2103276 T3 ES 2103276T3 ES 90914341 T ES90914341 T ES 90914341T ES 90914341 T ES90914341 T ES 90914341T ES 2103276 T3 ES2103276 T3 ES 2103276T3
Authority
ES
Spain
Prior art keywords
immune system
activation
composition
chemotherapy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914341T
Other languages
English (en)
Inventor
Spiros Jamas
D Davidson Easson Jr
Gary R Ostroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Beta Technology Inc
Original Assignee
Alpha Beta Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology Inc filed Critical Alpha Beta Technology Inc
Application granted granted Critical
Publication of ES2103276T3 publication Critical patent/ES2103276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Steroid Compounds (AREA)
  • Massaging Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

SE ADMINISTRAN GLUCANOS DE PAREDES DE CELULAS DE LEVADURA MODIFICADA A PACIENTES QUE CORREN EL RIESGO DE INFECTARSE DEBIDO A CIRUGIA INMINENTE, QUIMIOTERAPIA U OTRO TRATAMIENTO QUE AFECTA AL SISTEMA INMUNOLOGICO, PARA MOBILIZAR LOS MECANISMOS DE DEFENSA CELULAR Y ESTIMULA LA RESPUESTA INMUNOLOGICA DEL PACIENTE ANTES, DURANTE Y DESPUES DE LA CIRUGIA, QUIMIOTERAPIA U OTRO TRATAMIENTO.
ES90914341T 1989-09-08 1990-09-05 Composicion para la activacion del sistema inmunitario. Expired - Lifetime ES2103276T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40476589A 1989-09-08 1989-09-08

Publications (1)

Publication Number Publication Date
ES2103276T3 true ES2103276T3 (es) 1997-09-16

Family

ID=23600941

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914341T Expired - Lifetime ES2103276T3 (es) 1989-09-08 1990-09-05 Composicion para la activacion del sistema inmunitario.

Country Status (9)

Country Link
US (1) US5504079A (es)
EP (1) EP0491829B1 (es)
JP (1) JPH05502018A (es)
AT (1) ATE153856T1 (es)
AU (1) AU647751B2 (es)
CA (1) CA2067159A1 (es)
DE (1) DE69030880T2 (es)
ES (1) ES2103276T3 (es)
WO (1) WO1991003248A2 (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
AU698176B2 (en) * 1993-07-28 1998-10-29 Cis Bio International Radiolabelled glucans
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AU6261999A (en) 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20020123129A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading nitrogen-containing compounds
US20020123127A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for reducing odor
US20020123130A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading polymeric compounds
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
NO20014256D0 (no) * 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
CN1596116A (zh) * 2001-11-06 2005-03-16 东方癌症治疗株式会社 抗癌组合物
US20040001857A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Dietary supplements for treating hypertension
US7256026B2 (en) * 2002-06-28 2007-08-14 Ultra Biotech Limited Oral compositions for white blood cell activation and proliferation
US20040005336A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Dietary supplements for regulating the central nervous system
US20040001859A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
US20040005335A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Oral compositions for HIV-infected subjects
WO2005084692A2 (en) * 2003-08-13 2005-09-15 University Of Louisville Research Foundation, Inc. Effect of beta-glucan on stem cell recruitment and tissue repair
EP1545208A4 (en) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT
US20070042930A1 (en) * 2002-08-13 2007-02-22 Ross Gordon D Effect of beta-glucan on stem cell recruitment and tissue repair
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN100363054C (zh) 2002-09-04 2008-01-23 生物聚合物工程有限公司 全葡聚糖颗粒在抗癌药物中的应用
AU2004207565B2 (en) * 2003-01-29 2009-04-23 Immudyne, Inc. Immunopotentiating agent for use in animals
US7204986B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7226600B2 (en) * 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984507B2 (en) * 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7223400B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7201906B2 (en) * 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) * 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204987B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6989253B2 (en) * 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7223405B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) * 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US20040265990A1 (en) * 2003-06-30 2004-12-30 Cheung Ling Yuk Biological compositions for reduction of E. coli infections
US20050106705A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating hyperlipemia
US7297522B2 (en) * 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7078202B2 (en) * 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6964864B2 (en) * 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US20050106166A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating liver cirrhosis
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US7259001B2 (en) * 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
KR20060044829A (ko) * 2004-03-29 2006-05-16 다이소 가부시키가이샤 β-1,3-1,6-Ｄ-글루칸 및 그 용도
WO2006085895A2 (en) * 2004-05-10 2006-08-17 Biopolymer Engineering, Inc. Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
KR20070054246A (ko) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
EP1896601A1 (en) * 2005-06-15 2008-03-12 Medimush A/S Bioactive agents produced by submerged cultivation of a basidiomycete cell
WO2006133707A2 (en) 2005-06-15 2006-12-21 Medimush A/S Anti-cancer combination treatment and kit-of-part
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007146440A2 (en) 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
US20080063650A1 (en) * 2006-09-01 2008-03-13 Jun Yan mCRP antagonists and their uses
US8580253B2 (en) * 2006-11-06 2013-11-12 Whitehead Institute Immunomodulating compositions and methods of use
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
KR20090009513A (ko) * 2007-07-20 2009-01-23 한국원자력연구원 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸
KR20150064233A (ko) * 2007-09-27 2015-06-10 바이오테라, 인크. 상부 호흡기 감염 증상 및 심리적 웰빙의 베타-글루칸 처리
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
WO2011011617A1 (en) 2009-07-22 2011-01-27 Biothera, Inc. Therapeutic compositions and methods
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
ES2614181T3 (es) 2010-08-14 2017-05-30 University Of Massachusetts Partícula de pared celular de levadura para suministro de nanopartículas direccionadas al receptor
CA2932753A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
EP3137118A4 (en) 2014-05-01 2017-11-22 RXi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
WO2016007876A1 (en) 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
KR102689262B1 (ko) 2014-09-05 2024-07-30 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
ES2875338T3 (es) 2014-11-06 2021-11-10 Hibercell Inc Métodos de beta-glucano y composiciones que afectan al microentorno tumoral
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
EP3319614B1 (en) 2015-07-06 2020-12-23 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
KR20200072886A (ko) 2018-12-13 2020-06-23 주식회사 글루칸 흑효모 유래 바이오폴리머 생산을 위한 배지 조성물 및 그를 이용한 흑효모 유래 바이오폴리머의 제조방법
WO2021064088A1 (en) * 2019-10-04 2021-04-08 Universiteit Gent Beta-glucans having superior immuno-stimulating properties
CN115135765A (zh) 2019-11-08 2022-09-30 菲奥医药公司 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5571701A (en) * 1978-11-24 1980-05-30 Sankyo Co Ltd Hydrolyzate polysaccharide, its preparation, and immunoregulator containing hydrolyzate polysaccharide as active ingredient
JPS5676401A (en) * 1979-11-27 1981-06-24 Hitoshi Ito Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
FR2477416A1 (fr) * 1980-03-10 1981-09-11 Unicler Utilisation de hansenula ou d'extraits de hansenula, comme medicament
JPS5945301A (ja) * 1982-09-09 1984-03-14 Toyo Soda Mfg Co Ltd 多糖類及びその製造法
JPS59210901A (ja) * 1983-05-17 1984-11-29 Nippon Kinoko Kenkyusho プロテオグルカン及びそれからなる抗ガン剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan

Also Published As

Publication number Publication date
US5504079A (en) 1996-04-02
CA2067159A1 (en) 1991-03-09
AU647751B2 (en) 1994-03-31
JPH05502018A (ja) 1993-04-15
EP0491829A1 (en) 1992-07-01
ATE153856T1 (de) 1997-06-15
WO1991003248A2 (en) 1991-03-21
DE69030880T2 (de) 1997-09-18
AU6429290A (en) 1991-04-08
DE69030880D1 (de) 1997-07-10
EP0491829B1 (en) 1997-06-04
WO1991003248A3 (en) 1991-06-13

Similar Documents

Publication Publication Date Title
ES2103276T3 (es) Composicion para la activacion del sistema inmunitario.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
ATE271063T1 (de) Purin-l-nukleoside, deren analoga und verwendungen
NO943901L (no) Fremgangsmåter og preparater for behandling av sykdommer med interferon samtidig som bivirkninger reduseres
DK0522092T3 (da) Iontophoretisk medikamentindgiftssystem med to-trins-indgiftsprofil
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
BRPI0317064B8 (pt) composições compreendendo células dendríticas parcialmente amadurecidas in vitro
Foldi et al. Effect of complex decongestive physiotherapy on gene expression for the inflammatory response in peripheral lymphedema
Gray et al. Protective effect of pitressin and epinephrine against total body X-irradiation
AU5643299A (en) Humic acid and its use in the treatment of various conditions
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
DK0559145T3 (da) Lægemiddel til truende abort
PT1047422E (pt) Utilizacao de histamina para elevar os niveis de histamina no sangue
Ockelford et al. A double-blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (Fragmin) in patients having major elective general surgery
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
Jose et al. Levamisole in patients with recurrent herpes infection
IT1277926B1 (it) Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
Li et al. Intratumor therapy in rodents with aqueous clam extracts
RU2148988C1 (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
BABA et al. Potentiation of anticancer effect of carboquone in vivo by glucose pretreatment
Rajmane et al. Immunotherapy and Surgical Treatment of Eye Cancer in Bovine
Gilles A case of typhoid osteitis treated with chloramphenicol
RU94022334A (ru) Способ лечения и профилактики инвазионных заболеваний
PT1150981E (pt) Composto nucleosidico terapeutico
Lestina et al. Treatment of systemic lupus erythematosus with ACTH.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491829

Country of ref document: ES